Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
[The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat].
Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Alterations of the optic pathway between unilateral and bilateral optic nerve damage in multiple sclerosis as revealed by the combined use of advanced diffusion kurtosis imaging and visual evoked potentials.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
DNA strand breakage by peroxidase-activated mitoxantrone.
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
Clinical proteomics of enervated neurons.
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Pages
« first
‹ previous
…
48
49
50
51
52
53
54
55
56
…
next ›
last »